Key Takeaways:
Outlook Therapeutics (Nasdaq: OTLK) submitted a formal dispute resolution request to the U.S. Food and Drug Administration on April 7 for its wet age-related macular degeneration drug, ONS-5010.
The move follows a Type A meeting with the regulator concerning a Complete Response Letter (CRL) issued on December 30, 2025, the company said in a statement. A CRL indicates the FDA has completed its review of an application but decided it cannot be approved in its present form.
The Biologics License Application (BLA) was for ONS-5010, also known as LYTENAVA™ (bevacizumab-vikg), for the treatment of neovascular age-related macular degeneration, a leading cause of blindness in older adults. Outlook Therapeutics is a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for retinal diseases.
The outcome of the dispute resolution process is a critical binary event for the company. A successful appeal could reverse the FDA's decision and place ONS-5010 on the path to approval and commercialization, which would likely result in a significant increase in the company's stock price.
An unsuccessful dispute would represent a major setback, confirming the agency's rejection and potentially delaying any revenue from the drug for years. This would likely cause a sharp decline in the stock and force the company to conduct further clinical trials.
The formal dispute resolution request is the next step in the regulatory process. The FDA's response to the request will be the next major catalyst for investors.
This article is for informational purposes only and does not constitute investment advice.
